Vifor Consumer Health Ltd., a subsidiary of the santé business of Galenica Ltd. has signed an asset purchase agreement with Glaxo Smith Kline to acquire the wound careproducts Merfen and Vita-Merfen and all related intellectual property rights and the market authorizations in several jurisdictions.
Vifor Consumer Health is therefore entering a new market in the form of wound care and further expanding its position in the Swiss healthcare market.
Galenica is a diversified Group active throughout the healthcare market which, among other activities, develops, manufactures and markets pharmaceutical products, runs pharmacies, provides logistical and database services and sets up networks. With its two Business units Vifor Pharma and Galenica Santé, the Galenica Group enjoys a leading position in all its core business activities. A large part of the Group’s income is generated by international operations.
Kellerhals Carrard has advised Galenica Ltd. and Vifor Consumer Health Ltd. in the drafting and negotiating of the transaction with a team led by Beat Brechbühl (picture) and Cécile Matter.
Law Firms: Kellerhals Carrard;
Clients: Galenica AG;